Montesinos, Pau http://orcid.org/0000-0002-3275-5593
Kota, Vamsi
Brandwein, Joseph
Bousset, Pierre
Benner, Rebecca J.
Vandendries, Erik
Chen, Ying
McMullin, Mary Frances
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia
https://doi.org/10.1007/s00280-023-04516-9
Funding for this research was provided by:
Pfizer
Article History
Received: 27 October 2022
Accepted: 24 February 2023
First Online: 9 March 2023
Declarations
:
: Pau Montesinos has served as a consultant for Agios, Astellas, Celgene, Daiichi Sankyo, Forma Therapeutics, Glycomimetics, and Tolero Pharmaceutical; has been an advisor for AbbVie, Astellas, Celgene, Daiichi Sankyo, Incyte, Janssen, Karyopharm, Novartis, Pfizer, Sanofi, and Teva; has received research funding from AbbVie, Astellas, Celgene, Daiichi Sankyo, Janssen, Karyopharm, Novartis, Pfizer, and Teva; and has participated in speakers bureau for AbbVie, Astellas, Celgene, Daiichi Sankyo, Incyte, Janssen, Novartis, Pfizer, Sanofi, and Teva. Vamsi Kota has served as a consultant for Novartis and Pfizer; and has received research funding from Incyte. Joseph Brandwein has received honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Jazz, Pfizer, Roche, and Taiho. Pierre Bousset, Rebecca J. Benner, Erik Vandendries, and Ying Chen are employees of Pfizer and own stock in Pfizer. Mary Frances McMullin has been an advisor for AbbVie, Bristol Myers Squibb, Celgene, and Novartis; has received research funding from AOP Health and Bristol Myers Squibb; and has participated in speakers bureau for AOP Health and Novartis.